LAUSR

exclusion criteria. Seventh TNM edition was used. Totally 168 patients’ demographic data, surgery types, clinical and pathological stage, pre-operative SUVmax and C/T ratio was recorded. Differences between patients with recurrence after surgery and without recurrence was demonstrated. Survival rates were analysed by divided into 3 groups according to C/T ratio (0.25-0.5, 0.5-0.75, 0.75-1.0) and cutoff value 50% of C/T ratio. Result: Two groups (C/T<0.5 and C/ T1⁄40.5-1) did not differ according to comparable factors like visceral pleural invasion, subtype of adenocarcinoma, median SUVmax. Median follow up time was 35 months. 54 patients were died of whom 8 (68%) patients were in C/T ratio<0.5 and 46 patients (67.8%) were in C/T1⁄40.5-1 group. OS was 44.9±5.07 and PFS was 50.8±5.42 in C/ T<0.5 group. OS was 69.7±3.34 and PFS was 77.2±3.23 in C/T1⁄40.5-1 group (p>0.05). Three-year survival rate was 50% for C/T <0.5 and 72% for C/T1⁄40.5-1 group (p>0.05). Mean SUVmax is 8.05±6.04 for C/T<0.5 and 10.07±6.85 for C/T 50% (p1⁄4 0.43). Existence of visceral pleura invasion was higher in patients with C/T 50% (69 patients vs 6 patients, p1⁄40.05). In univariate analyses age, gender and SUVmax value and in multivariate analyses only surgery type and SUV max value were predictors for OS (Surgery type: HR:1.33 (1.04-1.70), p1⁄40.02 and SUVmax: HR:1.04(1.00-1.08), p1⁄40.04).For PFS, only surgery type had significance both unıvariate and multivariate analyses (Univariate: HR: 1.47 (1.15-1.89), p1⁄40.002 and multivariate: HR: 1.67 (1.25-2.23), p1⁄4<0.001). Conclusion: In pathological stage 1 lung adenocarcinomas, SUVmax and surgery type are important predictors for OS. For PFS only surgery type has significance. Even visceral pleura invasion rates are higher in C/T 0.5 group, SUVmax is superior to the C/T ratio for predicting prognosis particularly for solid type lung cancer.